<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Cancer</journal-id><journal-title>Molecular Cancer</journal-title><issn pub-type="epub">1476-4598</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1476-4598-7-84</article-id><article-id pub-id-type="pmid">18990233</article-id><article-id pub-id-type="doi">10.1186/1476-4598-7-84</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: Pathological significance in early- and late-onset breast carcinoma</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Sinha</surname><given-names>Satyabrata</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>satyabratasinha@gmail.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Singh</surname><given-names>Ratnesh K</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ratnein@gmail.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Alam</surname><given-names>Neyaz</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>humpty78in@yahoo.co.in</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Roy</surname><given-names>Anup</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>anuproy@vsnl.net</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Roychoudhury</surname><given-names>Susanta</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>susanta@iicb.res.in</email></contrib><contrib id="A6" corresp="yes" contrib-type="author"><name><surname>Panda</surname><given-names>Chinmay Kumar</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ckpanda.cnci@gmail.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, India</aff><aff id="I2"><label>2</label>Department of Surgical Oncology, Chittaranjan National Cancer Institute, Kolkata, India</aff><aff id="I3"><label>3</label>Department of Pathology, Medical College, Kolkata, India</aff><aff id="I4"><label>4</label>Molecular and Human Genetics Division, Indian Institute of Chemical Biology, Kolkata, India</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>6</day><month>11</month><year>2008</year></pub-date><volume>7</volume><fpage>84</fpage><lpage>84</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molecular-cancer.com/content/7/1/84"/><history><date date-type="received"><day>22</day><month>8</month><year>2008</year></date><date date-type="accepted"><day>6</day><month>11</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Sinha et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Sinha et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Sinha Satyabrata satyabratasinha@gmail.com </dc:author><dc:title> Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: Pathological significance in early- and late-onset breast carcinoma </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>Molecular Cancer 7(1): 84-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1476-4598(2008)7:1&#x0003c;84&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1476-4598</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Introduction</title><p>Younger women with breast carcinoma (BC) exhibits more aggressive pathologic features compared to older women; young age could be an independent predictor of adverse prognosis. To find any existing differences in the molecular pathogenesis of BC in both younger and older women, alterations at chromosomal (chr.) 9q22.32-22.33 region were studied owing to its association in wide variety of tumors. Present work focuses on comparative analysis of alterations of four candidate genes; PHF2, FANCC, PTCH1 and XPA located within 4.4 Mb region of the afore-said locus in two age groups of BC, as well as the interrelation and prognostic significance of alterations of these genes.</p></sec><sec sec-type="methods"><title>Methods</title><p>Deletion analysis of PHF2, FANCC, PTCH1 and XPA were examined in a subset of 47 early-onset (group-A: &#x02264; 40 years) and 59 late-onset (group-B: &#x0003e; 40 years) breast carcinomas using both microsatellite and exonic markers. Methylation Sensitive Restriction analysis (MSRA) was done to check for promoter methylation. Quantitative real-time polymerase chain reaction (Q-PCR) and immunohistochemisty (IHC) was done in some genes to see their relative mRNA and protein expressions respectively. Clinico-pathological correlation of different parameters as well as patient survival was calculated using different statistical softwares like EpiInfo 6.04b, SPSS 10.0 etc.</p></sec><sec><title>Results</title><p>Either age group exhibited high frequency of overall alterations in PHF2, FANCC and PTCH1 compared to XPA. Samples with alteration (deletion/methylation) in these genes showed reduced level of mRNA expression as seen by Q-PCR. Immunohistochemical analysis of FANCC and PTCH1 also supported this observation. Poor patient survival was noted in both age groups having alterations in FANCC. Similar result was also seen with PTCH1 and XPA alterations in group-A and PHF2 alterations in group-B. This reflected their roles as prognostic tools in the respective groups in which they were altered.</p></sec><sec><title>Conclusion</title><p>Overall alterations of PHF2, FANCC and PTCH1 were comparatively higher than XPA. Differential association of alterations in FANCC and PTCH1 with that of PHF2, XPA and two breast cancer susceptibility genes (BRCA1/BRCA2) in the two age groups suggests differences in their molecular pathogenesis and dysregulation of multiple DNA repair pathways as well as hedgehog dependent stem cell renewal pathway.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>Breast carcinoma (BC) is the second leading cause of cancer deaths and the most common cancer among women. About 23% of urban women in eastern India are affected by this disease [<xref ref-type="bibr" rid="B1">1</xref>]. Depending on age at onset, BC can be early-onset (&#x02264; 40 years) and late-onset (&#x0003e; 40 years) type. However, the cut-off value for early-onset BC varies among investigators, ranging from 35&#x02013;50 years. Significant differences in clinico-pathological features like large tumor size of higher grade, presence of positive lymph nodes, absence of steroid receptors, and high S-phase fraction in younger women with BC indicated altered biology and pathogenesis between these two groups of BC [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. Another report showed that in Asian population, BC patients below 40 years have tumors with a poorer prognostic profile. However, this did not translate into a poorer overall survival, and this might be attributable to more aggressive adjuvant treatment of younger patients [<xref ref-type="bibr" rid="B5">5</xref>]. All these reports suggested early-onset BC to be a biologically separate disease and independently predict more adverse outcomes. Thus, the molecular analysis of BC in the two age groups is pertinent to understand the differences in pathogenesis, if any. Our earlier studies on chromosomes (chrs.) 1p/q, 9p and 11p/q showed differential pattern of molecular alterations between the two age groups of BC [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. In order to understand the pathogenesis in detail our aim is to analyze the alterations in other chromosomal regions which showed frequent alterations in BC.</p><p>Cytogenetic analyses have revealed a variety of chromosomal aberrations at chr.9q22 in different malignancies including BC [<xref ref-type="bibr" rid="B7">7</xref>]. Comparative genomic hybridization (CGH) and flow-cytometric analyses also showed losses at chr.9q in BC [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. Studies in basal cell carcinoma (BCC), squamous cell carcinoma (SCC) as well as bladder, prostate, esophageal and blood cancer detected frequent loss of heterozygosity (LOH) at chr.9q22.3 [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. Significant correlation between losses of chr.9q22.3 with lymph node metastasis in BC is reported [<xref ref-type="bibr" rid="B13">13</xref>].</p><p>Chr.9q22.3 is a relatively broad region (8.71 Mb) harboring several putative tumor suppressor genes (TSGs). We focused primarily on a 4.4 Mb region between the chr.9q22.32-22.33 where DNA-damage repair genes like FANCC (Fanconi anaemia Complementation-group C), XPA (Xeroderma Pigmentosum A) as well as the hedgehog (HH) pathway associated gene PTCH1 (<italic>human homologue of Drosophila patched gene</italic>) are localized [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B16">16</xref>]. FANCC localized at chr.9q22.32 (96.89 Mb from p-ter) is associated with reconstitutive and self-renewal potential of haematopoietic stem cells [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. Its ablation leads to increased sensitivity to DNA crosslinking agents, loss of FANCD2 activation, and impaired homologous recombination due to poor functioning of the BRCA1-BRCA2-NBS1-RAD51 mediated DNA repair [<xref ref-type="bibr" rid="B19">19</xref>]. Deletion of FANCC in bladder carcinoma, mutations in young-onset pancreatic cancer and Fanconi Anaemia-C patients, and down-regulation in head and neck squamous cell carcinoma (HNSCC) are reported [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B22">22</xref>]. PTCH1 (350 Kb downstream to FANCC) is a key regulator in stem cell renewal hedgehog signaling pathway and functions as a tumor suppressor by inhibiting G<sub>1</sub>-S and G<sub>2</sub>-M phases of cell cycle. PTCH1 has been implicated in the development of medulloblastomas, glioblastomas, rhabdomyosarcomas, pancreatic cancers, and other soft tissue tumors [<xref ref-type="bibr" rid="B23">23</xref>]. A recent report suggested loss of PTCH1 in 19% of human breast cancers, and 33% of breast cancer cell lines [<xref ref-type="bibr" rid="B9">9</xref>]. Mutations in PTCH1 gene have been reported in nevoid basal cell carcinoma syndrome (NBCCS), familial BC and its loss induced tumor progression in basal cell carcinoma (BCC) [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. Furthermore, immunohistochemical analysis showed reduced expression of PTCH1 due to promoter methylation in BC [<xref ref-type="bibr" rid="B26">26</xref>]. XPA (2.23 Mb down-stream of PTCH1) gene is essential for assembly of the pre-incision complex during the processing of DNA damage via the nucleotide excision repair (NER) pathway [<xref ref-type="bibr" rid="B27">27</xref>-<xref ref-type="bibr" rid="B29">29</xref>]. Defects in NER are associated with several human autosomal recessive hereditary disorders, such as xeroderma pigmentosum and a marked predisposition to skin cancer (early BCC, SCC and melanoma); early internal tumors [<xref ref-type="bibr" rid="B30">30</xref>]. LOH in sporadic ovarian, colon, lung carcinomas and significant association between oral premalignant lesions and polymorphism of XPA are reported [<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>]. PHF2, a novel transcriptional regulatory gene associated with hereditary sensory neuropathy type 1 (HSN1) has also been identified at chr.9q22.32, 1.52 Mb upstream of FANCC [<xref ref-type="bibr" rid="B33">33</xref>]. However, its role in tumorigenesis is not yet well understood.</p><p>Thus, it is evident that alterations of these genes together could cumulatively increase genetic instability and cellular proliferation. Furthermore, study of co-alterations of these genes could be useful in diagnosis and prognosis of a disease. Thus an attempt was made in this study to analyze the alterations (deletion, methylation and expression) of PHF2, FANCC, PTCH1 and XPA in early- and late-onset BC of Indian patients and correlate them with clinico-pathological differences.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients, Tumor tissues and cell lines</title><p>One hundred six invasive breast carcinomas (BC) and their corresponding normal tissues or peripheral blood leukocytes (PBL) were randomly collected from 104 unrelated patients, undergoing surgery at the hospital of Chittaranjan National Cancer Institute, Kolkata, India and stored at -80&#x000b0;C over a period of 9 years (1999&#x02013;2007). The BC samples were segregated into early-onset BC (group-A: &#x02264; 40 years) and late-onset BC (group-B: &#x0003e; 40 years) depending on the age of the patient at onset of tumor. Informed consent from patients and Research Ethics Committee of the institute were obtained. All these tumors were graded and staged according to UICC TNM classification [<xref ref-type="bibr" rid="B34">34</xref>]. Detailed clinico-pathological histories of the patients are presented in Table <xref ref-type="table" rid="T1">1</xref>. Part of the freshly operated tissues was directly collected in TRIzol reagent (Invitrogen, USA) for RNA isolation and the rest for DNA extraction. The BC cell line MCF-7 was obtained from American Type Culture Collection and grown according to ATCC instructions.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinico-pathological parameters of early- and late-onset BC</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="3">Group A</td><td align="center" colspan="3">Group B</td></tr><tr><td></td><td colspan="3"><hr></hr></td><td colspan="3"><hr></hr></td></tr><tr><td align="center">Clinical features</td><td align="center">Case</td><td align="center">Mean age (years)</td><td align="center">Age range (years)</td><td align="center">Case</td><td align="center">Mean age (years)</td><td align="center">Age range (years)</td></tr></thead><tbody><tr><td align="left">Histological Type</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="right">Ductal</td><td align="center">45</td><td align="center">34</td><td align="center">25&#x02013;40</td><td align="center">59</td><td align="center">53</td><td align="center">41&#x02013;77</td></tr><tr><td align="right">Lobular</td><td align="center">2</td><td align="center">28</td><td align="center">20&#x02013;35</td><td align="center">0</td><td align="center">_</td><td align="center">_</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Clinical Stage</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="right">TNM Stage I</td><td align="center">1</td><td align="center">40</td><td align="center">40</td><td align="center">2</td><td align="center">48</td><td align="center">45&#x02013;50</td></tr><tr><td align="right">TNM Stage II</td><td align="center">7</td><td align="center">33</td><td align="center">23&#x02013;40</td><td align="center">21</td><td align="center">51</td><td align="center">42&#x02013;61</td></tr><tr><td align="right">TNM Stage III</td><td align="center">36</td><td align="center">35</td><td align="center">20&#x02013;40</td><td align="center">33</td><td align="center">53</td><td align="center">41&#x02013;77</td></tr><tr><td align="right">TNM Stage IV</td><td align="center">3</td><td align="center">37</td><td align="center">36&#x02013;38</td><td align="center">3</td><td align="center">57</td><td align="center">48&#x02013;72</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Tumor Differentiation</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="right">Grade 1</td><td align="center">4</td><td align="center">32</td><td align="center">20&#x02013;40</td><td align="center">8</td><td align="center">52</td><td align="center">43&#x02013;61</td></tr><tr><td align="right">Grade 2</td><td align="center">32</td><td align="center">33</td><td align="center">18&#x02013;40</td><td align="center">39</td><td align="center">47</td><td align="center">41&#x02013;42</td></tr><tr><td align="right">Grade 3</td><td align="center">11</td><td align="center">38</td><td align="center">33&#x02013;40</td><td align="center">12</td><td align="center">56</td><td align="center">42&#x02013;77</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Lymph Node</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="right">Positive</td><td align="center">33</td><td align="center">35</td><td align="center">26&#x02013;40</td><td align="center">48</td><td align="center">52</td><td align="center">42&#x02013;77</td></tr><tr><td align="right">Negative</td><td align="center">14</td><td align="center">31</td><td align="center">18&#x02013;40</td><td align="center">11</td><td align="center">51</td><td align="center">41&#x02013;65</td></tr></tbody></table></table-wrap></sec><sec><title>Microdissection and DNA Extraction</title><p>Contaminant normal cells in the samples were removed by manual microdissection from cryosections (5 &#x003bc;m) using surgical knives under a dissecting microscope [Leica MZ 16]. The representative sections from different regions of the specimens were stained with hematoxylin-eosin for diagnosis as well as for marking of tumor-rich regions. The microdissected samples containing at least 70&#x02013;80% tumor cells were taken for DNA isolation via proteinase-K digestion, followed by phenol/chloroform extraction procedure [<xref ref-type="bibr" rid="B35">35</xref>].</p></sec><sec><title>Deletion analysis of the candidate TSGs</title><p>Deletion analysis of the candidate genes was done using 6 microsatellite markers in the following order: Centromere- (PHF2: D9S1803, D9S197, D9S196), (FANCC: D9S1958), (PTCH1: D9S1816) and (XPA: D9S1714) &#x02013; Telomere, selected on the basis of their map positions and heterozygosity (Ensembl release 44; Genome Database). One exonic marker each from PHF2 exon-18 and FANCC exon-2 were designed using Primer3Input 0.4.0 software to see the homozygous/hemizygous deletion (HD/HED) status of these genes [Table <xref ref-type="table" rid="T2">2</xref>].</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Summary of oligonucleotides</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Primers</bold></td><td align="center"><bold>Location</bold></td><td align="center"><bold>Analytical purpose</bold></td><td align="center"><bold>Forward Primer</bold></td><td align="center"><bold>Reverse Primer</bold></td><td align="center"><bold>Size (bp)</bold></td></tr></thead><tbody><tr><td align="center">PHF2 Ex-18</td><td align="center">9q22.32</td><td align="center">HD/HED</td><td align="left">5'-ACTCCTGCCTGCAGACCAC-3'</td><td align="left">5'-CCTGCTCTTCCTCGTAGTCG-3'</td><td align="center">168</td></tr><tr><td align="center">FANCC Ex-2</td><td align="center">9q22.32</td><td align="center">HD/HED</td><td align="left">5'-TGGCTCAAGATTCAGTAGATCTTTC-3'</td><td align="left">5'-TTTCAAGGCTTCATACATCTTCC-3'</td><td align="center">158</td></tr><tr><td align="center">PHF2 promoter</td><td align="center">-893 to -670 region</td><td align="center">Methylation</td><td align="left">5'-GTGGTGTCCCAACCAGAAAC-3'</td><td align="left">5'-GGGACCCCGAGGATAAGATA-3'</td><td align="center">223</td></tr><tr><td align="center">FANCC promoter</td><td align="center">-319 to -144 region</td><td align="center">Methylation</td><td align="left">5'-TTTTACCCCGTTGACAAAGC-3'</td><td align="left">5'-CGGTACTGCTCCAGTGTTCC-3'</td><td align="center">175</td></tr><tr><td align="center">PTCH1 promoter</td><td align="center">-715 to -420 region</td><td align="center">Methylation</td><td align="left">5'-CGAGGAGCACAAGAAAGCAG-3'</td><td align="left">5'-AGAAAGAGCCAGCGAATCC-3'</td><td align="center">295</td></tr><tr><td align="center">XPA promoter Ex.1</td><td align="center">-126 to +56 region</td><td align="center">Methylation</td><td align="left">5'-AGGCGCTCTCACTCAGAAAG-3'</td><td align="left">5'-TCCGCGGGTTGCTCTAAA-3'</td><td align="center">182</td></tr><tr><td align="center">PTCH1 Ex.*23</td><td align="center">Intron 22&#x02013;23 to Ex.23</td><td align="center">SSCP</td><td align="left">5'-TCTAACCCACCCTCACCCTC-3'</td><td align="left">5'-ATTGCTAGGGCCAGAATGCC-3'</td><td align="center">226</td></tr><tr><td align="center">PTCH1 Ex.23</td><td align="center">Ex.23 to Intron 23&#x02013;24</td><td align="center">SSCP</td><td align="left">5'-TTCTGCCTCCGTGACTGTC-3'</td><td align="left">5'-CTCTAGGTCCCTTGGCTGC-3'</td><td align="center">265</td></tr><tr><td align="center">PHF2 Ex. 18&#x02013;19</td><td align="center">Coding regions of exons</td><td align="center">Q-PCR</td><td align="left">5'-ACTCCTGCCTGCAGACCAC-3'</td><td align="left">5'-TCGACCGGGACTTAAAGATG-3'</td><td align="center">257</td></tr><tr><td align="center">FANCC Ex. 7&#x02013;8</td><td align="center">Coding regions of exons</td><td align="center">Q-PCR</td><td align="left">5'-TGGAGGCTCTCCTCATCTGT-3'</td><td align="left">5'-GCATTCGATCCTTCTCAGACA-3'</td><td align="center">223</td></tr><tr><td align="center">PTCH1 Ex. 1&#x02013;2</td><td align="center">Coding regions of exons</td><td align="center">Q-PCR</td><td align="left">5'-GACCGGGACTATCTGCA-3'</td><td align="left">5'-GAGGAGGCCCACAACC-3'</td><td align="center">186</td></tr><tr><td align="center">&#x003b2;2 Microglobulin</td><td align="center">15q21-q22.2</td><td align="center">Q-PCR</td><td align="left">5'-GTGCTCGCGCTACTCTCTCT-3'</td><td align="left">5'-TCAATGTCGGATGGATGAAA-3'</td><td align="center">153</td></tr><tr><td align="center">&#x003b2;-3A-adaptin (K1*)</td><td align="center">5q14.1</td><td align="center">DNA cleavage control</td><td align="left">5'-TGCCCTCTGGACTGGAACCT-3'</td><td align="left">5'-CCTGAGCCCAGCCCAAGTC-3'</td><td align="center">445</td></tr><tr><td align="center">RAR&#x003b2;2 (K2**)</td><td align="center">3p24.2</td><td align="center">DNA integrity control</td><td align="left">5'-AGAGTTTGATGGAGTTGGGT-3'</td><td align="left">5'-CATTCGGTTTGGGTCAATCC-3'</td><td align="center">229</td></tr></tbody></table></table-wrap><p>To detect for deletion in informative microsatellite markers, standard polymerase chain reaction (PCR) analysis with [&#x003b3;-p32] ATP end labeled forward primer was done in a 20 &#x003bc;l reaction volume as described previously [<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. Multiplex PCR was done to see deletion (HD/HED) in the non-informative markers [<xref ref-type="bibr" rid="B35">35</xref>]. The D9S104 marker at chr.9p13 was used as control (CL) due to low frequency of alterations seen in BC (data not shown). The PCR products were run on 2% agarose gel, stained with ethidium bromide and visualized under UV transluminator.</p><p>Using a densitometric scanner (Bio-Rad GS-800, USA) the number of alleles at LOI (locus of interest) was determined from the signal intensities according to the following formula:</p><p><disp-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1" name="1476-4598-7-84-i1" overflow="scroll"><mml:semantics><mml:mrow><mml:mtext>Allele&#x000a0;Number</mml:mtext><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mfrac><mml:mrow><mml:mtext>LOI</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mtext>T</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:mtext>CL</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mtext>T</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mtext>LOI</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mtext>N</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:mtext>CL</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mtext>N</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:semantics></mml:math></disp-formula></p><p>Where T = tumor DNA; N = normal DNA; CL = Control; LOI = Locus of Interest</p><p>Allelic values of &#x02264; 0.5, 0.9 &#x02013; 1.7, &#x02265; 1.8 to &#x0003c; 5.0 and &#x0003e; 5.0 will be considered as homozygous deletion (HD), hemizygous deletion (HED), retention of homozygosity (RA) and amplification of the alleles respectively [<xref ref-type="bibr" rid="B37">37</xref>].</p></sec><sec><title>PCR based Methylation sensitive restriction analysis (MSRA)</title><p>Promoter methylation of PHF2, FANCC, PTCH1 and XPA were done in all BC samples by MSRA using methyl-sensitive restriction enzyme HpaII and its methylation in-sensitive iso-schizomer MspI [<xref ref-type="bibr" rid="B38">38</xref>]. Primer sequences are listed in Table <xref ref-type="table" rid="T2">2</xref>. Promoter region of PTCH1 gene harbored 6 CCGG-recognition sites for the above restriction enzymes while, there were two CCGG sites in FANCC promoter and one each in PHF2 and XPA gene promoters. The 445-bp fragment of &#x003b2;-3A adaptin gene (K1) and 229-bp fragment of RAR&#x003b2;2 exon-1 (K2) was used as digestion and integrity controls respectively [<xref ref-type="bibr" rid="B39">39</xref>].</p></sec><sec><title>Mutation analysis</title><p>Mutation analysis of exon-23 of PTCH1 was done in 60 BC samples by single strand conformation polymorphism (SSCP) analysis using [&#x003b1;-p32] dCTP as described previously [<xref ref-type="bibr" rid="B36">36</xref>]. Two primers from exon 23 (Ex*23 and Ex-23) were designed to cover the entire exon-23 which is a mutational hotspot and reported to be mutated in a variety of cancers [Table <xref ref-type="table" rid="T2">2</xref>]. Sequencing for both strands of the samples showing abnormal band shift in autoradiographs were done using 3100-Avant Genetic Analyzer (PE Applied Biosystems Inc, USA).</p></sec><sec><title>Quantitative Real-time PCR (Q-PCR)</title><p>The mRNA expression of PHF2, FANCC, PTCH1 and XPA in normal breast tissue (n = 6), and primary BC (n = 14) and 1 cell line (MCF-7) was analyzed by quantitative real-time (Q-PCR). Total RNA was isolated from samples using TRIzol reagent according to the manufacturer's protocol (Ambion Inc.). Complementary-DNA (cDNA) was synthesized from 1 &#x003bc;g total RNA using Random hexamer (Invitrogen, USA) and Superscript III (Invitrogen, USA) according to manufacturer's protocol. PCR was performed in 40 cycles on an ABI Prism 7500 using Power SYBR Green PCR Master Mix (Applied Biosystems, USA) in a final volume of 15 &#x003bc;l. Each sample was run in triplicates and average value was considered for analysis. Relative quantities (&#x00394;&#x00394;Ct) were obtained by normalization against human beta2-microglobulin gene [<xref ref-type="bibr" rid="B40">40</xref>]. Primers are listed in Table <xref ref-type="table" rid="T2">2</xref>.</p></sec><sec><title>Immunohistochemistry</title><p>Immunostaining of FANCC and PTCH1 protein were done in 20 primary breast carcinomas using the Avidin-Biotin-Peroxidase Complex (ABC) staining kit according to manufacturers protocol (Santa Cruz Biotechnology, CA, USA). About 3&#x02013;5 &#x003bc;m paraffin sections were de-paraffinized, rehydrated and reacted overnight with primary antibodies (goat polyclonal IgG, sc-18110 for FANCC (C-14) and sc-6149 for PTCH1 (G-19); Santa Cruz, CA, USA) at a dilution of 1:100 at 4&#x000b0;C. Horse-Radish-Peroxidase conjugated rabbit anti-goat secondary antibody (sc-2768) was added at 1:500 dilutions. The slides were developed using 3-3' diaminobenzidine (DAB) as the chromogen and counterstained with hematoxylin. The staining intensity (- = negative, + = weak, 2+ = moderate, and 3+ = strong) and the percentage of positive cells (- = 0%, + = 1&#x02013;24%, 2+ = 25&#x02013;49%, and 3+ = 50&#x02013;100%) were evaluated by two observers independently [<xref ref-type="bibr" rid="B41">41</xref>].</p></sec><sec><title>Statistical Analysis of Clinical Data</title><p>Fisher's exact test was used to determine the association between tumors genetic profile and different clinico-pathological features. Survival analysis was performed according to Kaplan-Meier method. Post-operative overall survival was measured from the date of surgery to the date of last follow-up or death (up to 5 years). Probability value (P-value) &#x02264; 0.05 was considered statistically significant. All the statistical analysis was performed using statistical programs EpiInfo 6.04b, SPSS 10.0 (SPSS Inc. Chicago, IL, USA).</p></sec></sec><sec><title>Results</title><sec><title>Deletion analysis of candidate TSGs loci</title><p>Deletion mapping identified LOH in microsatellite markers and both hemi/homozygous deletion in the exonic markers [Figure <xref ref-type="fig" rid="F1">1</xref>]. Compared to XPA, high deletion was seen in the PHF2, FANCC and PTCH1 loci in both age groups of BC [Figure <xref ref-type="fig" rid="F2">2</xref>; Additional Files <xref ref-type="supplementary-material" rid="S1">1</xref> and <xref ref-type="supplementary-material" rid="S2">2</xref>]. Order of deletion frequencies were: group-A: FANCC (47%) &#x0003e; PHF2 (43%) &#x0003e; PTCH1 (30%) &#x0003e; XPA (21%) and group-B: FANCC (49%) &#x0003e; PHF2 (42%) &#x0003e; PTCH1 (27%) &#x0003e; XPA (20%). LOH was concordant with hemizygous deletion in exonic markers. Homozygous deletions were restricted to PHF2 exon-18 and FANCC exon-2. Interstitial deletion or loss of entire region was observed in 32% (15/47) group-A and 42% (25/59) group-B samples indicating the importance of this region in BC.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>(a) Representative autoradiograph showing loss of heterozygosity (LOH) (b) homozygous/hemizygous deletion (HD/HED) analysis in microsatellite markers (c) HD/HED of exonic markers.</bold> &#x02192; indicates loss of corresponding alleles.</p></caption><graphic xlink:href="1476-4598-7-84-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Pattern of deletion at different chr.9q22.32-22.33 markers in early- and late-onset BC.</p></caption><graphic xlink:href="1476-4598-7-84-2"/></fig><p>Deletion between PTCH1 and XPA was significantly associated in both group-A (P = 0.02) and group-B (P = 0.00003) [Table <xref ref-type="table" rid="T3">3</xref>].</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Association between deletions of the 4 candidate genes in early- and late-onset BC</p></caption><table frame="hsides" rules="groups"><tbody><tr><td></td><td></td><td align="center" colspan="8"><bold>Group-A</bold></td><td align="center" colspan="8"><bold>Group-B</bold></td></tr><tr><td></td><td></td><td colspan="8"><hr></hr></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td></td><td align="center" colspan="2"><bold>PHF2</bold></td><td align="center" colspan="2"><bold>FANCC</bold></td><td align="center" colspan="2"><bold>PTCH1</bold></td><td align="center" colspan="2"><bold>XPA</bold></td><td align="center" colspan="2"><bold>PHF2</bold></td><td align="center" colspan="2"><bold>FANCC</bold></td><td align="center" colspan="2"><bold>PTCH1</bold></td><td align="center" colspan="2"><bold>XPA</bold></td></tr><tr><td></td><td></td><td colspan="8"><hr></hr></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td></td><td align="center"><bold>D+</bold></td><td align="center"><bold>D-</bold></td><td align="center"><bold>D+</bold></td><td align="center"><bold>D-</bold></td><td align="center"><bold>D+</bold></td><td align="center"><bold>D-</bold></td><td align="center"><bold>D+</bold></td><td align="center"><bold>D-</bold></td><td align="center"><bold>D+</bold></td><td align="center"><bold>D-</bold></td><td align="center"><bold>D+</bold></td><td align="center"><bold>D-</bold></td><td align="center"><bold>D+</bold></td><td align="center"><bold>D-</bold></td><td align="center"><bold>D+</bold></td><td align="center"><bold>D-</bold></td></tr><tr><td colspan="10"><hr></hr></td><td colspan="8"><hr></hr></td></tr><tr><td align="center"><bold>PHF2</bold></td><td align="center"><bold>D+</bold></td><td align="center">-</td><td align="center">-</td><td align="center">9</td><td align="center">11</td><td align="center">6</td><td align="center">14</td><td align="center">6</td><td align="center">14</td><td align="center">-</td><td align="center">-</td><td align="center">13</td><td align="center">12</td><td align="center">5</td><td align="center">20</td><td align="center">6</td><td align="center">19</td></tr><tr><td></td><td colspan="1"><hr></hr></td><td></td><td></td><td colspan="6"><hr></hr></td><td></td><td></td><td colspan="6"><hr></hr></td></tr><tr><td></td><td align="center"><bold>D-</bold></td><td></td><td></td><td align="center">13</td><td align="center">14</td><td align="center">8</td><td align="center">19</td><td align="center">4</td><td align="center">23</td><td></td><td></td><td align="center">16</td><td align="center">18</td><td align="center">11</td><td align="center">23</td><td align="center">6</td><td align="center">28</td></tr><tr><td colspan="10"><hr></hr></td><td colspan="8"><hr></hr></td></tr><tr><td align="center" colspan="2"><bold>p value</bold></td><td align="center" colspan="2">-</td><td align="center" colspan="2">0.83</td><td align="center" colspan="2">0.98</td><td align="center" colspan="2">0.21</td><td align="center" colspan="2">-</td><td align="center" colspan="2">0.71</td><td align="center" colspan="2">0.29</td><td align="center" colspan="2">0.55</td></tr><tr><td colspan="10"><hr></hr></td><td colspan="8"><hr></hr></td></tr><tr><td align="center"><bold>FANCC</bold></td><td align="center"><bold>D+</bold></td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">5</td><td align="center">17</td><td align="center">5</td><td align="center">17</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">7</td><td align="center">22</td><td align="center">5</td><td align="center">24</td></tr><tr><td></td><td colspan="1"><hr></hr></td><td></td><td></td><td></td><td></td><td colspan="4"><hr></hr></td><td></td><td></td><td></td><td></td><td colspan="4"><hr></hr></td></tr><tr><td></td><td align="center"><bold>D-</bold></td><td></td><td></td><td></td><td></td><td align="center">9</td><td align="center">16</td><td align="center">5</td><td align="center">20</td><td></td><td></td><td></td><td></td><td align="center">9</td><td align="center">21</td><td align="center">7</td><td align="center">23</td></tr><tr><td colspan="10"><hr></hr></td><td colspan="8"><hr></hr></td></tr><tr><td align="center" colspan="2"><bold>p value</bold></td><td align="center" colspan="2">-</td><td align="center" colspan="2">-</td><td align="center" colspan="2">0.32</td><td align="center" colspan="2">0.82</td><td align="center" colspan="2">-</td><td align="center" colspan="2">-</td><td align="center" colspan="2">0.61</td><td align="center" colspan="2">0.56</td></tr><tr><td colspan="10"><hr></hr></td><td colspan="8"><hr></hr></td></tr><tr><td align="center"><bold>PTCH1</bold></td><td align="center"><bold>D+</bold></td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">6</td><td align="center">8</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">9</td><td align="center">7</td></tr><tr><td></td><td colspan="1"><hr></hr></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2"><hr></hr></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2"><hr></hr></td></tr><tr><td></td><td align="center"><bold>D-</bold></td><td></td><td></td><td></td><td></td><td></td><td></td><td align="center">4</td><td align="center">29</td><td></td><td></td><td></td><td></td><td></td><td></td><td align="center">3</td><td align="center">40</td></tr><tr><td colspan="10"><hr></hr></td><td colspan="8"><hr></hr></td></tr><tr><td align="center" colspan="2"><bold>p value</bold></td><td align="center" colspan="2">-</td><td align="center" colspan="2">-</td><td align="center" colspan="2">-</td><td align="center" colspan="2"><bold>0.02*</bold></td><td align="center" colspan="2">-</td><td align="center" colspan="2">-</td><td align="center" colspan="2">-</td><td align="center" colspan="2"><bold>0.00003*</bold></td></tr></tbody></table><table-wrap-foot><p>Abbreviations used are: D+: Deletion positive; D-: Deletion negative; * indicates p value significance</p></table-wrap-foot></table-wrap></sec><sec><title>Promoter Methylation analysis</title><p>Comparable frequencies of promoter methylation were observed in both age groups. In group-A, PTCH1 exhibited highest 32% methylation followed by FANCC (30%), PHF2 (21%) and XPA (17%). Contrastingly, in group-B, FANCC showed highest 39% methylation followed by 36% in PTCH1, 24% in XPA and 22% in PHF2 [Figure <xref ref-type="fig" rid="F3">3</xref>; Additional File <xref ref-type="supplementary-material" rid="S3">3</xref>]. Concomitant methylation in all the candidate genes was observed in two early-onset and five late-onset BC samples.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>(a) Histogram showing pattern of methylation in the four genes.</bold> (b) Representative agarose gels showing methylation in PHF2, FANCC, PTCH1 and XPA done by MSRA. H, HpaII digested DNA; M, MspI digested DNA; U, undigested DNA. Controls: A 445-bp fragment of &#x003b2;3A adaptin gene (K1) and 229-bp fragment of RAR&#x003b2;2 exon-1 (K2).</p></caption><graphic xlink:href="1476-4598-7-84-3"/></fig><p>Significant association was observed between methylation of FANCC and PHF2 in both group-A (P = 0.02) and group-B (P = 0.001). Methylation of XPA was significantly associated with methylation of PHF2 (P = 0.03) and FANCC (P = 0.0001) in group-A and that of PTCH1 (P = 0.01) in group-B [Table <xref ref-type="table" rid="T4">4</xref>]. In FANCC, both deletion and methylation showed significant association in both groups (P = 0.004 and 0.002) while, in PTCH1 significant association was observed only in group-A (P = 0.002) [data no shown].</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Association between methylation of the 4 candidate genes in early- and late-onset BC</p></caption><table frame="hsides" rules="groups"><tbody><tr><td></td><td></td><td align="center" colspan="8"><bold>Group-A</bold></td><td align="center" colspan="8"><bold>Group-B</bold></td></tr><tr><td></td><td></td><td colspan="8"><hr></hr></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td></td><td align="center" colspan="2"><bold>PHF2</bold></td><td align="center" colspan="2"><bold>FANCC</bold></td><td align="center" colspan="2"><bold>PTCH1</bold></td><td align="center" colspan="2"><bold>XPA</bold></td><td align="center" colspan="2"><bold>PHF2</bold></td><td align="center" colspan="2"><bold>FANCC</bold></td><td align="center" colspan="2"><bold>PTCH1</bold></td><td align="center" colspan="2"><bold>XPA</bold></td></tr><tr><td></td><td></td><td colspan="8"><hr></hr></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td></td><td align="center"><bold>M+</bold></td><td align="center"><bold>M-</bold></td><td align="center"><bold>M+</bold></td><td align="center"><bold>M-</bold></td><td align="center"><bold>M+</bold></td><td align="center"><bold>M-</bold></td><td align="center"><bold>M+</bold></td><td align="center"><bold>M-</bold></td><td align="center"><bold>M+</bold></td><td align="center"><bold>M-</bold></td><td align="center"><bold>M+</bold></td><td align="center"><bold>M-</bold></td><td align="center"><bold>M+</bold></td><td align="center"><bold>M-</bold></td><td align="center"><bold>M+</bold></td><td align="center"><bold>M-</bold></td></tr><tr><td colspan="10"><hr></hr></td><td colspan="8"><hr></hr></td></tr><tr><td align="center"><bold>PHF2</bold></td><td align="center"><bold>M+</bold></td><td align="center">-</td><td align="center">-</td><td align="center">6</td><td align="center">4</td><td align="center">2</td><td align="center">8</td><td align="center">4</td><td align="center">6</td><td align="center">-</td><td align="center">-</td><td align="center">10</td><td align="center">3</td><td align="center">7</td><td align="center">6</td><td align="center">5</td><td align="center">8</td></tr><tr><td></td><td colspan="1"><hr></hr></td><td></td><td></td><td colspan="6"><hr></hr></td><td></td><td></td><td colspan="6"><hr></hr></td></tr><tr><td></td><td align="center"><bold>M-</bold></td><td></td><td></td><td align="center">8</td><td align="center">29</td><td align="center">13</td><td align="center">24</td><td align="center">4</td><td align="center">33</td><td></td><td></td><td align="center">13</td><td align="center">33</td><td align="center">14</td><td align="center">32</td><td align="center">9</td><td align="center">37</td></tr><tr><td colspan="10"><hr></hr></td><td colspan="8"><hr></hr></td></tr><tr><td align="center" colspan="2"><bold>p value</bold></td><td align="center" colspan="2">-</td><td align="center" colspan="2"><bold>0.02*</bold></td><td align="center" colspan="2">0.36</td><td align="center" colspan="2"><bold>0.03*</bold></td><td align="center" colspan="2">-</td><td align="center" colspan="2"><bold>0.001*</bold></td><td align="center" colspan="2">0.12</td><td align="center" colspan="2">0.16</td></tr><tr><td colspan="10"><hr></hr></td><td colspan="8"><hr></hr></td></tr><tr><td align="center"><bold>FANCC</bold></td><td align="center"><bold>M+</bold></td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">6</td><td align="center">8</td><td align="center">7</td><td align="center">7</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">7</td><td align="center">16</td><td align="center">7</td><td align="center">16</td></tr><tr><td></td><td colspan="1"><hr></hr></td><td></td><td></td><td></td><td></td><td colspan="4"><hr></hr></td><td></td><td></td><td></td><td></td><td colspan="4"><hr></hr></td></tr><tr><td></td><td align="center"><bold>M-</bold></td><td></td><td></td><td></td><td></td><td align="center">9</td><td align="center">24</td><td align="center">1</td><td align="center">32</td><td></td><td></td><td></td><td></td><td align="center">14</td><td align="center">22</td><td align="center">7</td><td align="center">29</td></tr><tr><td colspan="10"><hr></hr></td><td colspan="8"><hr></hr></td></tr><tr><td align="center" colspan="2"><bold>p value</bold></td><td align="center" colspan="2">-</td><td align="center" colspan="2">-</td><td align="center" colspan="2">0.29</td><td align="center" colspan="2"><bold>0.0001*</bold></td><td align="center" colspan="2">-</td><td align="center" colspan="2">-</td><td align="center" colspan="2">0.51</td><td align="center" colspan="2">0.33</td></tr><tr><td colspan="10"><hr></hr></td><td colspan="8"><hr></hr></td></tr><tr><td align="center"><bold>PTCH1</bold></td><td align="center"><bold>M+</bold></td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">4</td><td align="center">11</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">9</td><td align="center">12</td></tr><tr><td></td><td colspan="1"><hr></hr></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2"><hr></hr></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2"><hr></hr></td></tr><tr><td></td><td align="center"><bold>M-</bold></td><td></td><td></td><td></td><td></td><td></td><td></td><td align="center">4</td><td align="center">28</td><td></td><td></td><td></td><td></td><td></td><td></td><td align="center">5</td><td align="center">33</td></tr><tr><td colspan="10"><hr></hr></td><td colspan="8"><hr></hr></td></tr><tr><td align="center" colspan="2"><bold>p value</bold></td><td align="center" colspan="2">-</td><td align="center" colspan="2">-</td><td align="center" colspan="2">-</td><td align="center" colspan="2">0.23</td><td align="center" colspan="2">-</td><td align="center" colspan="2">-</td><td align="center" colspan="2">-</td><td align="center" colspan="2"><bold>0.01*</bold></td></tr></tbody></table><table-wrap-foot><p>Abbreviations used are: M+: Methylation positive; M-: Methylation negative; * indicates p value significance</p></table-wrap-foot></table-wrap></sec><sec><title>Mutation analysis of PTCH1 Exon-23</title><p>SSCP analysis in 60 primary BC samples revealed no abnormal band shifts in PTCH1 exon-23. Direct sequencing of 20 out of these 60 samples showed no changes in the nucleotide sequences.</p></sec><sec><title>Association between overall alterations of candidate TSGs</title><p>Either deletion or methylation of any one of the 4 candidate genes were seen in about 91% of the samples in both groups indicating the importance of chr.9q22.32-22.33 in the development of BC. Overall alterations (deletion/methylation) of PHF2, FANCC, PTCH1 and XPA were comparable in both age groups, them showing 60%, 53%, 43% and 36% alterations respectively in group-A and 59%, 59%, 58% and 36% in group-B (Figure <xref ref-type="fig" rid="F4">4</xref>; Additional File <xref ref-type="supplementary-material" rid="S4">4</xref>). Overall alterations of PTCH1 showed significant association with XPA in both group-A (P = 0.003) and group-B (P = 0.007). However, overall alterations of PHF2 showed significant association with either FANCC (P = 0.005) or XPA (P = 0.05) only in group-B [data not shown].</p><fig position="float" id="F4"><label>Figure 4</label><caption><p>Patten of overall alterations in 4 candidate genes at chr9q22.32-22.33.</p></caption><graphic xlink:href="1476-4598-7-84-4"/></fig></sec><sec><title>Expression analysis of the candidate genes</title><p>Q-PCR analysis of PHF2, FANCC and PTCH1 mRNA revealed reduced mRNA expression of in all these genes. In respect to non-tumor control, relative fold reduction in expression of these genes in primary tumors was seen in the following order: FANCC (31.6 &#x000b1; 36.7) &#x0003e; PHF2 (26.54 &#x000b1; 44.41) &#x0003e; PTCH1 (19.3 &#x000b1; 27.8). Reduced expression was noted in nearly 33&#x02013;40% of the tumors, greater than the mean fold in reduction of the respective genes [Figure <xref ref-type="fig" rid="F5">5</xref>; Additional File <xref ref-type="supplementary-material" rid="S5">5</xref>]. Immunohistochemical analysis showed both FANCC [Figure <xref ref-type="fig" rid="F6">6a&#x02013;c</xref>] and PTCH1 proteins [Figure <xref ref-type="fig" rid="F6">6d&#x02013;f</xref>] to be localized exclusively within the cytoplasm. Strong cytoplasmic staining in genes observed in samples with no alterations (deletion and/or methylation) of the candidate genes, while moderate to negative expression was observed in samples harboring genetic and/or epigenetic alterations. Table <xref ref-type="table" rid="T5">5</xref> indicates significant association between alterations of FANCC (P = 0.004) and PTCH1 (P = 0.001) genes with their protein expression as seen by immunohistochemistry. The immunohistochemical analysis of PHF2 was not done due to the lack of commercially available antibody.</p><fig position="float" id="F5"><label>Figure 5</label><caption><p><bold>Box plot representing the relative expression level of PHF2, FANCC and PTCH1 genes done by Q-PCR as shown in the <italic>y</italic>-axis.</bold> Each box shows the distribution of expression levels from 25th to 75th percentile. The median is shown as a line across the box, whereas the '+' is the calculated mean expression level for the particular subtype. Overall, the cases consistently had lower expression of the candidate TSGs.</p></caption><graphic xlink:href="1476-4598-7-84-5"/></fig><fig position="float" id="F6"><label>Figure 6</label><caption><p><bold>Immunohistochemistry of FANCC and PTCH1 (a-c) FANCC expression pattern (d-f) PTCH1 expression pattern.</bold> BC samples showing high (a and d) or moderate (b and e) or low (c and f) expression of FANCC and PTCH1 genes respectively. Arrow (&#x02192;) indicates the expression pattern of FANCC and PTCH1 in primary BC. All magnifications are at 20&#x000d7;.</p></caption><graphic xlink:href="1476-4598-7-84-6"/></fig><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Immunohistochemical expression of FANCC and PTCH1 with respect to their alterations</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><bold>FANCC alteration</bold></td><td></td><td align="center"><bold>PTCH1 alteration</bold></td><td></td></tr><tr><td></td><td colspan="1"><hr></hr></td><td></td><td colspan="1"><hr></hr></td><td></td></tr><tr><td align="center"><bold>Sample No.</bold></td><td align="center"><bold>Deletion/Methylation</bold></td><td align="center"><bold>FANCC protein expression</bold></td><td align="center"><bold>Deletion/Methylation</bold></td><td align="center"><bold>PTCH1 protein expression</bold></td></tr></thead><tbody><tr><td align="center">1186</td><td align="center">+/-</td><td align="center">-</td><td align="center">-/-</td><td align="center">+++</td></tr><tr><td align="center">374</td><td align="center">-/+</td><td align="center">-</td><td align="center">-/+</td><td align="center">-</td></tr><tr><td align="center">4187</td><td align="center">+/-</td><td align="center">+</td><td align="center">-/+</td><td align="center">-</td></tr><tr><td align="center">3266</td><td align="center">+/+</td><td align="center">-</td><td align="center">-/-</td><td align="center">+++</td></tr><tr><td align="center">5451</td><td align="center">-/-</td><td align="center">+++</td><td align="center">-/-</td><td align="center">+++</td></tr><tr><td align="center">5596</td><td align="center">-/-</td><td align="center">+++</td><td align="center">-/+</td><td align="center">-</td></tr><tr><td align="center">3156</td><td align="center">+/+</td><td align="center">-</td><td align="center">-/-</td><td align="center">+++</td></tr><tr><td align="center">4604</td><td align="center">+/+</td><td align="center">-</td><td align="center">+/+</td><td align="center">-</td></tr><tr><td align="center">4131</td><td align="center">-/+</td><td align="center">++</td><td align="center">+/-</td><td align="center">-</td></tr><tr><td align="center">2490</td><td align="center">+/-</td><td align="center">-</td><td align="center">-/+</td><td align="center">-</td></tr><tr><td align="center">2400</td><td align="center">+/+</td><td align="center">-</td><td align="center">-/+</td><td align="center">++</td></tr><tr><td align="center">796</td><td align="center">+/-</td><td align="center">++</td><td align="center">-/+</td><td align="center">-</td></tr><tr><td align="center">880</td><td align="center">-/-</td><td align="center">+++</td><td align="center">+/+</td><td align="center">-</td></tr><tr><td align="center">314</td><td align="center">+/-</td><td align="center">++</td><td align="center">+/-</td><td align="center">++</td></tr><tr><td align="center">5337</td><td align="center">+/-</td><td align="center">-</td><td align="center">-/-</td><td align="center">+++</td></tr><tr><td align="center">1865</td><td align="center">+/+</td><td align="center">-</td><td align="center">-/+</td><td align="center">-</td></tr><tr><td align="center">4671</td><td align="center">-/-</td><td align="center">+++</td><td align="center">+/-</td><td align="center">+</td></tr><tr><td align="center">3025</td><td align="center">+/+</td><td align="center">-</td><td align="center">-/+</td><td align="center">-</td></tr><tr><td align="center">6155</td><td align="center">-/+</td><td align="center">-</td><td align="center">-/-</td><td align="center">+++</td></tr><tr><td align="center">1144</td><td align="center">-/-</td><td align="center">+++</td><td align="center">-/+</td><td align="center">-</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="center"><bold>P value</bold></td><td align="center" colspan="2"><bold>P = 0.004 *</bold></td><td align="center" colspan="2"><bold>P = 0.001 *</bold></td></tr></tbody></table><table-wrap-foot><p>Abbreviations used are: Sample no is patient's registration number</p></table-wrap-foot></table-wrap></sec><sec><title>Association with some DNA repair genes</title><p>Of the 106 BC samples a subset of 29 group-A and 33 group-B breast samples were further studied to find out the association between the candidate genes with some breast cancer susceptibility genes like BRCA1, BRCA2 that are intermittently associated with breast cancer. Deletion status of BRCA1 and BRCA2 in the 29 group-A and 33 group-B samples has already been reported [<xref ref-type="bibr" rid="B42">42</xref>]. Overall alterations of FANCC showed significant association with deletion of BRCA2 in both group-A (P = 0.03) and group-B (P = 0.02). However, only in group-A, significant association was observed between overall alterations of PTCH1 and deletion of BRCA1 (P = 0.04) [Additional File <xref ref-type="supplementary-material" rid="S6">6</xref>].</p></sec><sec><title>Clinico-pathological association and patient survival</title><p>In group-A, both deletion and methylation of PTCH1 were significantly associated with advanced stages. Moreover, its deletion in group-A and methylation in group-B were significantly associated with higher tumor grades (P = 0.02) and lymph node metastasis (P = 0.03) respectively. Methylation of XPA also showed significant association with lymph node invasion (P = 0.04) in group-A [Additional Files <xref ref-type="supplementary-material" rid="S7">7</xref> and <xref ref-type="supplementary-material" rid="S8">8</xref>].</p><p>The clinical outcome in the two age groups was investigated for a period of 5 years. The patient follow-up ranged from 2&#x02013;60 months in both age groups. The mean and median follow-up period in group-A was 32 months each while, in group-B it was 35 months and 39 months respectively. Log-rank test uncovered statistically significant differences in overall patient survival between cases with presence and absence of any alteration (deletion and/or methylation) in FANCC (P = 0.005), PTCH1 (P = 0.03) and XPA (P = &#x0003c; 0.00001) among group-A samples. However in group-B samples, alterations of only FANCC (P = 0.01) was significantly associated with survival [Figure <xref ref-type="fig" rid="F7">7</xref>].</p><fig position="float" id="F7"><label>Figure 7</label><caption><p><bold>Kaplan-Meier 5-year survival probability curves with cumulative survival of BC patients by alteration status of PHF2, FANCC, PTCH1 and XPA in (A.) early-onset and (B.) late-onset BC.</bold> Survival time was defined as the time from surgery to the patient's death, known recurrence or the last time the patient was known to be alive. The log rank test was used to assess the differences in the patient survival between cases with plot for the differences in overall survival among cases with any alteration (Deletion +ve/Alteration -ve or Deletion -ve/Methylation +ve or Deletion +ve/Methylation +ve) and no alteration (Deletion -ve/Methylation -ve) of the analyzed genes. <italic>N </italic> denotes sample size.</p></caption><graphic xlink:href="1476-4598-7-84-7"/></fig></sec></sec><sec><title>Discussion</title><p>Previous studies have shown differences in alteration pattern of various chromosomal regions in the development of early- and late-onset BC [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. To delineate the molecular pathogenesis of BC in the two age groups in detail, molecular alterations (deletion/methylation) of candidate genes PHF2, FANCC, PTCH1 and XPA within chr.9q22.32-22.33 region were analyzed due to its association with a wide variety of tumors including BC. Nearly 91% samples in both groups presented alterations in any one of the genes. Compared to XPA, overall frequencies of alterations in PHF2, FANCC and PTCH1 were higher (Figure <xref ref-type="fig" rid="F4">4</xref>). This is the first report of its kind. The overall alterations of these genes were differentially associated in the two age groups and indicated differences in pathogenesis and adverse prognosis in patients.</p><p>Significant association between deletion and methylation of FANCC in both groups and PTCH1 in group-A only, suggested them to be candidate TSGs in BC. The concordance between deletion/methylation of these genes with protein expression also supported this fact. Down-regulation in mRNA expression of these genes were also seen in MCF-7 and primary BC samples. Deletion, mutation and down-regulation of FANCC have also been reported in other malignancies [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B22">22</xref>]. Significant association of FANCC-XPA methylation in group-A and FANCC-BRCA2 deletion in both age groups supported interlink between multiple DNA repair pathways. This warrants further analysis of other members of this repair pathway needs to be done. The association noted between FANCC alterations and adverse patient survival in either age group suggests it as a prognostic marker.</p><p>Contrary to previous reports, frequencies of alterations in PTCH1 in our samples were higher [<xref ref-type="bibr" rid="B9">9</xref>]. This may be due to differences in etiology, ethnicity and techniques used in our study. Mutations in exon-23 of PTCH1 were reported in BCC but, no such changes were seen in our samples [<xref ref-type="bibr" rid="B43">43</xref>]. Significant association between PTCH1 and XPA deletion in both groups as well as between their methylation in group-B suggested some functional relationship between hedgehog dependent stem cell renewal pathway and the NER pathway. Coincident germline mutations in PTCH1 and BRCA1 genes have been seen in familial BC and NBCCS [<xref ref-type="bibr" rid="B24">24</xref>]. Similarly, correlation between PTCH1 alterations with BRCA1 deletion in group-A suggested its association with other DNA repair pathways. Poor survival in group-A patients with PTCH1 alterations indicated its prognostic significance. In PHF2 and XPA no association was seen between their deletion and methylation. So, other mechanisms of inactivation such as mutation cannot be ruled out. High deletion along with significant association of PHF2 methylation with FANCC methylation in both age groups and XPA methylation in group-A suggested PHF2 to be a candidate TSGs in BC. Reduced expression of PHF2 mRNA also supported this fact. Further analysis of PHF2 is required to assess its role in tumorigenesis.</p></sec><sec><title>Conclusion</title><p>Thus it may be concluded that impairment of multiple DNA repair pathways and PTCH1 associated self-renewal pathway are necessary for the development of both groups of BC. However, differential association of these genes with adverse patient outcome in both groups suggests their differences in molecular pathogenesis.</p></sec><sec><title>Abbreviations</title><p>ATCC: American Type Culture Collection; BC: Breast carcinoma; BCC: basal cell carcinoma; CGH: Comparative Genomic Hybridization; Chr.: Chromosome; HD: Homozygous deletion; HED: Hemizygous deletion; IHC: Immunohistochemisty; LOH: loss of heterozygosity; MSRA: Methylation Sensitive Restriction Analysis; NBCCS: nevoid basal cell carcinoma syndrome; NER: nucleotide excision repair; Q-PCR: Quantitative Real-time Polymerase Chain Reaction; SCC: squamous cell carcinoma; UICC: International Union against Cancer</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>SS carried out the molecular genetic studies, participated in the sequence alignment and drafted the manuscript. RKS participated in the design of the study and performed the statistical analysis. NA provided the samples needed for this study. AR carried the histological studies. SR participated in its design and coordination and helped to draft the manuscript. CKP conceived of the study, and participated in its design and coordination and helped to draft the manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>Pattern of alterations in early-onset (&#x02264; 40 years) breast carcinoma.</bold></p></caption><media xlink:href="1476-4598-7-84-S1.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p><bold>Pattern of alterations in late-onset (&#x0003e; 40 years) breast carcinoma.</bold></p></caption><media xlink:href="1476-4598-7-84-S2.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S3"><caption><title>Additional file 3</title><p><bold>Frequency of methylation of chr.9q22.32-22.33 candidate genes in early- and late-onset breast carcinoma.</bold></p></caption><media xlink:href="1476-4598-7-84-S3.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S4"><caption><title>Additional file 4</title><p><bold>Frequency of overall alterations (deletion/methylation) of candidate TSGs in breast carcinoma.</bold></p></caption><media xlink:href="1476-4598-7-84-S4.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S5"><caption><title>Additional file 5</title><p><bold>Q-PCR data sheet for expression analysis of candidate TSGs.</bold></p></caption><media xlink:href="1476-4598-7-84-S5.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S6"><caption><title>Additional file 6</title><p><bold>Association between overall alterations of the candidate TSGs at chr.9q22.32-22.33 and other DNA repair genes in early- and late-onset BC.</bold></p></caption><media xlink:href="1476-4598-7-84-S6.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S7"><caption><title>Additional file 7</title><p><bold>Clinico-pathological correlation of deletion in different genes at chr.9q22.32-22.33 in Group-A and Group-B breast carcinomas.</bold></p></caption><media xlink:href="1476-4598-7-84-S7.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S8"><caption><title>Additional file 8</title><p><bold>Clinico-pathological correlation of methylation in different genes at chr.9q22.32-22.33 in Group-A and Group-B breast carcinomas.</bold></p></caption><media xlink:href="1476-4598-7-84-S8.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>We are thankful to the Director, Chittaranjan National Cancer Institute, Kolkata-700026, India. I am also grateful to Dr. Sukta Das for her invaluable contribution in preparing the manuscript. Financial support was provided by CSIR &#x02013; JRF/NET Fellowship grant [no. 9/30(031)/2003- EMR-I] to Mr. S. Sinha.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>U</given-names></name><name><surname>Sankaranarayanan</surname><given-names>R</given-names></name><name><surname>Mandal</surname><given-names>S</given-names></name><name><surname>Ramanakumar</surname><given-names>AV</given-names></name><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Siddiqi</surname><given-names>M</given-names></name></person-group><article-title>Cancer patterns in eastern India: the first report of the Kolkata cancer registry</article-title><source>Int J Cancer</source><year>2002</year><volume>100</volume><fpage>86</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">12115592</pub-id><pub-id pub-id-type="doi">10.1002/ijc.10446</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>HR</given-names></name><name><surname>Bland</surname><given-names>KI</given-names></name><name><surname>Wanebo</surname><given-names>HJ</given-names></name></person-group><article-title>Younger women with breast carcinoma have a poorer prognosis than older women</article-title><source>Cancer</source><year>1996</year><volume>77</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">8630946</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19960101)77:1&#x0003c;97::AID-CNCR16&#x0003e;3.0.CO;2-3</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chunder</surname><given-names>N</given-names></name><name><surname>Mandal</surname><given-names>S</given-names></name><name><surname>Basu</surname><given-names>D</given-names></name><name><surname>Roy</surname><given-names>A</given-names></name><name><surname>Roychoudhury</surname><given-names>S</given-names></name><name><surname>Panda</surname><given-names>CK</given-names></name></person-group><article-title>Deletion mapping of chromosome 1 in early onset and late onset breast tumors&#x02013;a comparative study in eastern India</article-title><source>Pathol Res Pract</source><year>2003</year><volume>199</volume><fpage>313</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">12908521</pub-id><pub-id pub-id-type="doi">10.1078/0344-0338-00423</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chunder</surname><given-names>N</given-names></name><name><surname>Mandal</surname><given-names>S</given-names></name><name><surname>Roy</surname><given-names>A</given-names></name><name><surname>Roychoudhury</surname><given-names>S</given-names></name><name><surname>Panda</surname><given-names>CK</given-names></name></person-group><article-title>Analysis of different deleted regions in chromosome 11 and their interrelations in early- and late-onset breast tumors: association with cyclin D1 amplification and survival</article-title><source>Diagn Mol Pathol</source><year>2004</year><volume>13</volume><fpage>172</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">15322430</pub-id><pub-id pub-id-type="doi">10.1097/01.pas.0000124337.49401.0b</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foo</surname><given-names>CS</given-names></name><name><surname>Su</surname><given-names>D</given-names></name><name><surname>Chong</surname><given-names>CK</given-names></name><name><surname>Chng</surname><given-names>HC</given-names></name><name><surname>Tay</surname><given-names>KH</given-names></name><name><surname>Low</surname><given-names>SC</given-names></name><name><surname>Tan</surname><given-names>SM</given-names></name></person-group><article-title>Breast cancer in young Asian women: study on survival</article-title><source>ANZ J Surg</source><year>2005</year><volume>75</volume><fpage>566</fpage><lpage>572</lpage><pub-id pub-id-type="pmid">15972049</pub-id><pub-id pub-id-type="doi">10.1111/j.1445-2197.2005.03431.x</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Chunder</surname><given-names>N</given-names></name><name><surname>Mukherjee</surname><given-names>N</given-names></name><name><surname>Alam</surname><given-names>N</given-names></name><name><surname>Roy</surname><given-names>A</given-names></name><name><surname>Roychoudhury</surname><given-names>S</given-names></name><name><surname>Kumar Panda</surname><given-names>C</given-names></name></person-group><article-title>Frequent deletion and methylation in SH3GL2 and CDKN2A loci are associated with early- and late-onset breast carcinoma</article-title><source>Ann Surg Oncol</source><year>2008</year><volume>15</volume><fpage>1070</fpage><lpage>1080</lpage><pub-id pub-id-type="pmid">18239974</pub-id><pub-id pub-id-type="doi">10.1245/s10434-007-9790-0</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitelman</surname><given-names>F</given-names></name><name><surname>Mertens</surname><given-names>F</given-names></name><name><surname>Johansson</surname><given-names>B</given-names></name></person-group><article-title>A breakpoint map of recurrent chromosomal rearrangements in human neoplasia</article-title><source>Nat Genet</source><year>1997</year><fpage>417</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">9140409</pub-id><pub-id pub-id-type="doi">10.1038/ng0497supp-417</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>AN</given-names></name><name><surname>Chin</surname><given-names>K</given-names></name><name><surname>Borresen-Dale</surname><given-names>AL</given-names></name><name><surname>Erikstein</surname><given-names>BK</given-names></name><name><surname>Eynstein Lonning</surname><given-names>P</given-names></name><name><surname>Kaaresen</surname><given-names>R</given-names></name><name><surname>Gray</surname><given-names>JW</given-names></name></person-group><article-title>Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><fpage>7952</fpage><lpage>7957</lpage><pub-id pub-id-type="pmid">11438741</pub-id><pub-id pub-id-type="doi">10.1073/pnas.151241198</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naylor</surname><given-names>TL</given-names></name><name><surname>Greshock</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Colligon</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>QC</given-names></name><name><surname>Clemmer</surname><given-names>V</given-names></name><name><surname>Zaks</surname><given-names>TZ</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name></person-group><article-title>High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization</article-title><source>Breast Cancer Res</source><year>2005</year><volume>7</volume><fpage>R1186</fpage><lpage>1198</lpage><pub-id pub-id-type="pmid">16457699</pub-id><pub-id pub-id-type="doi">10.1186/bcr1356</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Korsching</surname><given-names>E</given-names></name><name><surname>Packeisen</surname><given-names>J</given-names></name><name><surname>Helms</surname><given-names>MW</given-names></name><name><surname>Kersting</surname><given-names>C</given-names></name><name><surname>Voss</surname><given-names>R</given-names></name><name><surname>van Diest</surname><given-names>PJ</given-names></name><name><surname>Brandt</surname><given-names>B</given-names></name><name><surname>Wall</surname><given-names>E van der</given-names></name><name><surname>Boecker</surname><given-names>W</given-names></name><name><surname>Burger</surname><given-names>H</given-names></name></person-group><article-title>Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry</article-title><source>Br J Cancer</source><year>2004</year><volume>90</volume><fpage>1422</fpage><lpage>1428</lpage><pub-id pub-id-type="pmid">15054466</pub-id><pub-id pub-id-type="doi">10.1038/sj.bjc.6601658</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lichun</surname><given-names>Y</given-names></name><name><surname>Ching Tang</surname><given-names>CM</given-names></name><name><surname>Wai Lau</surname><given-names>K</given-names></name><name><surname>Lung</surname><given-names>ML</given-names></name></person-group><article-title>Frequent loss of heterozygosity on chromosome 9 in Chinese esophageal squamous cell carcinomas</article-title><source>Cancer Lett</source><year>2004</year><volume>203</volume><fpage>71</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">14670619</pub-id><pub-id pub-id-type="doi">10.1016/j.canlet.2003.09.027</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simoneau</surname><given-names>M</given-names></name><name><surname>LaRue</surname><given-names>H</given-names></name><name><surname>Aboulkassim</surname><given-names>TO</given-names></name><name><surname>Meyer</surname><given-names>F</given-names></name><name><surname>Moore</surname><given-names>L</given-names></name><name><surname>Fradet</surname><given-names>Y</given-names></name></person-group><article-title>Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest</article-title><source>Oncogene</source><year>2000</year><volume>19</volume><fpage>6317</fpage><lpage>6323</lpage><pub-id pub-id-type="pmid">11175346</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1204022</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simoneau</surname><given-names>M</given-names></name><name><surname>Aboulkassim</surname><given-names>TO</given-names></name><name><surname>LaRue</surname><given-names>H</given-names></name><name><surname>Rousseau</surname><given-names>F</given-names></name><name><surname>Fradet</surname><given-names>Y</given-names></name></person-group><article-title>Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><fpage>157</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">9926930</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1202277</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nowakowska</surname><given-names>B</given-names></name><name><surname>Kutkowska-Kazmierczak</surname><given-names>A</given-names></name><name><surname>Stankiewicz</surname><given-names>P</given-names></name><name><surname>Bocian</surname><given-names>E</given-names></name><name><surname>Obersztyn</surname><given-names>E</given-names></name><name><surname>Ou</surname><given-names>Z</given-names></name><name><surname>Cheung</surname><given-names>SW</given-names></name><name><surname>Cai</surname><given-names>WW</given-names></name></person-group><article-title>A girl with deletion 9q22.1-q22.32 including the PTCH and ROR2 genes identified by genome-wide array-CGH</article-title><source>Am J Med Genet A</source><year>2007</year><volume>143A</volume><fpage>1885</fpage><lpage>1889</lpage><pub-id pub-id-type="pmid">17632781</pub-id><pub-id pub-id-type="doi">10.1002/ajmg.a.31845</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D'Alessandro</surname><given-names>M</given-names></name><name><surname>Coats</surname><given-names>SE</given-names></name><name><surname>Morley</surname><given-names>SM</given-names></name><name><surname>Mackintosh</surname><given-names>L</given-names></name><name><surname>Tessari</surname><given-names>G</given-names></name><name><surname>Turco</surname><given-names>A</given-names></name><name><surname>Gerdes</surname><given-names>AM</given-names></name><name><surname>Pichert</surname><given-names>G</given-names></name><name><surname>Whittaker</surname><given-names>S</given-names></name><name><surname>Brandrup</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Multiple self-healing squamous epithelioma in different ethnic groups: more than a founder mutation disorder?</article-title><source>J Invest Dermatol</source><year>2007</year><volume>127</volume><fpage>2336</fpage><lpage>2344</lpage><pub-id pub-id-type="pmid">17554363</pub-id><pub-id pub-id-type="doi">10.1038/sj.jid.5700914</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wreesmann</surname><given-names>VB</given-names></name><name><surname>Estilo</surname><given-names>C</given-names></name><name><surname>Eisele</surname><given-names>DW</given-names></name><name><surname>Singh</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>SJ</given-names></name></person-group><article-title>Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma</article-title><source>ORL J Otorhinolaryngol Relat Spec</source><year>2007</year><volume>69</volume><fpage>218</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">17409780</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haneline</surname><given-names>LS</given-names></name><name><surname>Gobbett</surname><given-names>TA</given-names></name><name><surname>Ramani</surname><given-names>R</given-names></name><name><surname>Carreau</surname><given-names>M</given-names></name><name><surname>Buchwald</surname><given-names>M</given-names></name><name><surname>Yoder</surname><given-names>MC</given-names></name><name><surname>Clapp</surname><given-names>DW</given-names></name></person-group><article-title>Loss of FancC function results in decreased hematopoietic stem cell repopulating ability</article-title><source>Blood</source><year>1999</year><volume>94</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10381491</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Habi</surname><given-names>O</given-names></name><name><surname>Delisle</surname><given-names>MC</given-names></name><name><surname>Messier</surname><given-names>N</given-names></name><name><surname>Carreau</surname><given-names>M</given-names></name></person-group><article-title>Lack of self-renewal capacity in Fancc-/- stem cells after ex vivo expansion</article-title><source>Stem Cells</source><year>2005</year><volume>23</volume><fpage>1135</fpage><lpage>1141</lpage><pub-id pub-id-type="pmid">16020692</pub-id><pub-id pub-id-type="doi">10.1634/stemcells.2004-0356</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kitao</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Matsushita</surname><given-names>N</given-names></name><name><surname>Ohzeki</surname><given-names>M</given-names></name><name><surname>Ishiai</surname><given-names>M</given-names></name><name><surname>Takata</surname><given-names>M</given-names></name></person-group><article-title>Functional interplay between BRCA2/FancD1 and FancC in DNA repair</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><fpage>21312</fpage><lpage>21320</lpage><pub-id pub-id-type="pmid">16687415</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M603290200</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neveling</surname><given-names>K</given-names></name><name><surname>Kalb</surname><given-names>R</given-names></name><name><surname>Florl</surname><given-names>AR</given-names></name><name><surname>Herterich</surname><given-names>S</given-names></name><name><surname>Friedl</surname><given-names>R</given-names></name><name><surname>Hoehn</surname><given-names>H</given-names></name><name><surname>Hader</surname><given-names>C</given-names></name><name><surname>Hartmann</surname><given-names>FH</given-names></name><name><surname>Nanda</surname><given-names>I</given-names></name><name><surname>Steinlein</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Disruption of the FA/BRCA pathway in bladder cancer</article-title><source>Cytogenet Genome Res</source><year>2007</year><volume>118</volume><fpage>166</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">18000367</pub-id><pub-id pub-id-type="doi">10.1159/000108297</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heijden</surname><given-names>MS van der</given-names></name><name><surname>Yeo</surname><given-names>CJ</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Kern</surname><given-names>SE</given-names></name></person-group><article-title>Fanconi anemia gene mutations in young-onset pancreatic cancer</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>2585</fpage><lpage>2588</lpage><pub-id pub-id-type="pmid">12750283</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Couch</surname><given-names>FJ</given-names></name><name><surname>Johnson</surname><given-names>MR</given-names></name><name><surname>Rabe</surname><given-names>K</given-names></name><name><surname>Boardman</surname><given-names>L</given-names></name><name><surname>McWilliams</surname><given-names>R</given-names></name><name><surname>de Andrade</surname><given-names>M</given-names></name><name><surname>Petersen</surname><given-names>G</given-names></name></person-group><article-title>Germ line Fanconi anemia complementation group C mutations and pancreatic cancer</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>383</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">15695377</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shahi</surname><given-names>MH</given-names></name><name><surname>Lorente</surname><given-names>A</given-names></name><name><surname>Castresana</surname><given-names>JS</given-names></name></person-group><article-title>Hedgehog signalling in medulloblastoma, glioblastoma and neuroblastoma</article-title><source>Oncol Rep</source><year>2008</year><volume>19</volume><fpage>681</fpage><lpage>688</lpage><pub-id pub-id-type="pmid">18288402</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reifenberger</surname><given-names>J</given-names></name><name><surname>Arnold</surname><given-names>N</given-names></name><name><surname>Kiechle</surname><given-names>M</given-names></name><name><surname>Reifenberger</surname><given-names>G</given-names></name><name><surname>Hauschild</surname><given-names>A</given-names></name></person-group><article-title>Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer</article-title><source>J Invest Dermatol</source><year>2001</year><volume>116</volume><fpage>472</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">11231326</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adolphe</surname><given-names>C</given-names></name><name><surname>Hetherington</surname><given-names>R</given-names></name><name><surname>Ellis</surname><given-names>T</given-names></name><name><surname>Wainwright</surname><given-names>B</given-names></name></person-group><article-title>Patched1 functions as a gatekeeper by promoting cell cycle progression</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>2081</fpage><lpage>2088</lpage><pub-id pub-id-type="pmid">16489008</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2146</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>I</given-names></name><name><surname>Bose</surname><given-names>S</given-names></name><name><surname>Desmond</surname><given-names>JC</given-names></name><name><surname>Lin</surname><given-names>BT</given-names></name><name><surname>Williamson</surname><given-names>EA</given-names></name><name><surname>Karlan</surname><given-names>BY</given-names></name><name><surname>Koeffler</surname><given-names>HP</given-names></name></person-group><article-title>Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer</article-title><source>Breast Cancer Res Treat</source><year>2007</year><volume>105</volume><fpage>139</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">17295047</pub-id><pub-id pub-id-type="doi">10.1007/s10549-006-9440-4</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asahina</surname><given-names>H</given-names></name><name><surname>Kuraoka</surname><given-names>I</given-names></name><name><surname>Shirakawa</surname><given-names>M</given-names></name><name><surname>Morita</surname><given-names>EH</given-names></name><name><surname>Miura</surname><given-names>N</given-names></name><name><surname>Miyamoto</surname><given-names>I</given-names></name><name><surname>Ohtsuka</surname><given-names>E</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name></person-group><article-title>The XPA protein is a zinc metalloprotein with an ability to recognize various kinds of DNA damage</article-title><source>Mutat Res</source><year>1994</year><volume>315</volume><fpage>229</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">7526200</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuraoka</surname><given-names>I</given-names></name><name><surname>Morita</surname><given-names>EH</given-names></name><name><surname>Saijo</surname><given-names>M</given-names></name><name><surname>Matsuda</surname><given-names>T</given-names></name><name><surname>Morikawa</surname><given-names>K</given-names></name><name><surname>Shirakawa</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name></person-group><article-title>Identification of a damaged-DNA binding domain of the XPA protein</article-title><source>Mutat Res</source><year>1996</year><volume>362</volume><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">8538652</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patrick</surname><given-names>SM</given-names></name><name><surname>Turchi</surname><given-names>JJ</given-names></name></person-group><article-title>Xeroderma pigmentosum complementation group A protein (XPA) modulates RPA-DNA interactions via enhanced complex stability and inhibition of strand separation activity</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>16096</fpage><lpage>16101</lpage><pub-id pub-id-type="pmid">11859086</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M200816200</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>KL</given-names></name><name><surname>Karagas</surname><given-names>MR</given-names></name><name><surname>Kraft</surname><given-names>P</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Catalano</surname><given-names>PJ</given-names></name><name><surname>Byler</surname><given-names>SH</given-names></name><name><surname>Nelson</surname><given-names>HH</given-names></name></person-group><article-title>XPA, haplotypes, and risk of basal and squamous cell carcinoma</article-title><source>Carcinogenesis</source><year>2006</year><volume>27</volume><fpage>1670</fpage><lpage>1675</lpage><pub-id pub-id-type="pmid">16513681</pub-id><pub-id pub-id-type="doi">10.1093/carcin/bgi376</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Spitz</surname><given-names>MR</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Lippman</surname><given-names>SM</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name></person-group><article-title>Nucleotide excision repair pathway genes and oral premalignant lesions</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>3753</fpage><lpage>3758</lpage><pub-id pub-id-type="pmid">17575242</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-1911</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takebayashi</surname><given-names>Y</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name><name><surname>Kanzaki</surname><given-names>A</given-names></name><name><surname>Miyashita</surname><given-names>H</given-names></name><name><surname>Ogura</surname><given-names>O</given-names></name><name><surname>Mori</surname><given-names>S</given-names></name><name><surname>Mutoh</surname><given-names>M</given-names></name><name><surname>Miyazaki</surname><given-names>K</given-names></name><name><surname>Fukumoto</surname><given-names>M</given-names></name><name><surname>Pommier</surname><given-names>Y</given-names></name></person-group><article-title>Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumors</article-title><source>Cancer Lett</source><year>2001</year><volume>174</volume><fpage>115</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">11689286</pub-id><pub-id pub-id-type="doi">10.1016/S0304-3835(01)00690-5</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hasenpusch-Theil</surname><given-names>K</given-names></name><name><surname>Chadwick</surname><given-names>BP</given-names></name><name><surname>Theil</surname><given-names>T</given-names></name><name><surname>Heath</surname><given-names>SK</given-names></name><name><surname>Wilkinson</surname><given-names>DG</given-names></name><name><surname>Frischauf</surname><given-names>AM</given-names></name></person-group><article-title>PHF2, a novel PHD finger gene located on human chromosome 9q22</article-title><source>Mamm Genome</source><year>1999</year><volume>10</volume><fpage>294</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">10051327</pub-id><pub-id pub-id-type="doi">10.1007/s003359900989</pub-id></citation></ref><ref id="B34"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Sobin</surname><given-names>LH</given-names></name><name><surname>Wittekind</surname><given-names>C</given-names></name></person-group><source>TNM Classification of Malignant Tumors</source><year>2002</year><edition>6</edition><publisher-name>New York: Wiley</publisher-name></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dasgupta</surname><given-names>S</given-names></name><name><surname>Mukherjee</surname><given-names>N</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Roy</surname><given-names>A</given-names></name><name><surname>Sengupta</surname><given-names>A</given-names></name><name><surname>Roychowdhury</surname><given-names>S</given-names></name><name><surname>Panda</surname><given-names>CK</given-names></name></person-group><article-title>Mapping of the candidate tumor suppressor genes' loci on human chromosome 3 in head and neck squamous cell carcinoma of an Indian patient population</article-title><source>Oral Oncol</source><year>2002</year><volume>38</volume><fpage>6</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">11755815</pub-id><pub-id pub-id-type="doi">10.1016/S1368-8375(00)00131-7</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tripathi Bhar</surname><given-names>A</given-names></name><name><surname>Banerjee</surname><given-names>S</given-names></name><name><surname>Chunder</surname><given-names>N</given-names></name><name><surname>Roy</surname><given-names>A</given-names></name><name><surname>Sengupta</surname><given-names>A</given-names></name><name><surname>Roy</surname><given-names>B</given-names></name><name><surname>Roychowdhury</surname><given-names>S</given-names></name><name><surname>Panda</surname><given-names>CK</given-names></name></person-group><article-title>Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients</article-title><source>J Cancer Res Clin Oncol</source><year>2003</year><volume>129</volume><fpage>642</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">14586645</pub-id><pub-id pub-id-type="doi">10.1007/s00432-003-0485-z</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ichimura</surname><given-names>K</given-names></name><name><surname>Bolin</surname><given-names>MB</given-names></name><name><surname>Goike</surname><given-names>HM</given-names></name><name><surname>Schmidt</surname><given-names>EE</given-names></name><name><surname>Moshref</surname><given-names>A</given-names></name><name><surname>Collins</surname><given-names>VP</given-names></name></person-group><article-title>Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><fpage>417</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">10667596</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loginov</surname><given-names>VI</given-names></name><name><surname>Maliukova</surname><given-names>AV</given-names></name><name><surname>Seregin Iu</surname><given-names>A</given-names></name><name><surname>Khodyrev</surname><given-names>DS</given-names></name><name><surname>Kazubskaia</surname><given-names>TP</given-names></name><name><surname>Ermilova</surname><given-names>VD</given-names></name><name><surname>Gar'kavtseva</surname><given-names>RF</given-names></name><name><surname>Kiselev</surname><given-names>LL</given-names></name><name><surname>Zabarovskii</surname><given-names>ER</given-names></name><name><surname>Braga</surname><given-names>EA</given-names></name></person-group><article-title>[Methylation of the promoter region of the RASSF1A gene, a candidate tumor suppressor, in primary epithelial tumors]</article-title><source>Mol Biol (Mosk)</source><year>2004</year><volume>38</volume><fpage>654</fpage><lpage>667</lpage><pub-id pub-id-type="pmid">15456137</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ivanova</surname><given-names>T</given-names></name><name><surname>Petrenko</surname><given-names>A</given-names></name><name><surname>Gritsko</surname><given-names>T</given-names></name><name><surname>Vinokourova</surname><given-names>S</given-names></name><name><surname>Eshilev</surname><given-names>E</given-names></name><name><surname>Kobzeva</surname><given-names>V</given-names></name><name><surname>Kisseljov</surname><given-names>F</given-names></name><name><surname>Kisseljova</surname><given-names>N</given-names></name></person-group><article-title>Methylation and silencing of the retinoic acid receptor-beta 2 gene in cervical cancer</article-title><source>BMC Cancer</source><year>2002</year><volume>2</volume><fpage>4</fpage><pub-id pub-id-type="pmid">11945179</pub-id><pub-id pub-id-type="doi">10.1186/1471-2407-2-4</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method</article-title><source>Methods</source><year>2001</year><volume>25</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">11846609</pub-id><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milde-Langosch</surname><given-names>K</given-names></name><name><surname>Bamberger</surname><given-names>AM</given-names></name><name><surname>Rieck</surname><given-names>G</given-names></name><name><surname>Kelp</surname><given-names>B</given-names></name><name><surname>Loning</surname><given-names>T</given-names></name></person-group><article-title>Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype</article-title><source>Breast Cancer Res Treat</source><year>2001</year><volume>67</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">11518467</pub-id><pub-id pub-id-type="doi">10.1023/A:1010623308275</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chunder</surname><given-names>N</given-names></name><name><surname>Mandal</surname><given-names>S</given-names></name><name><surname>Roy</surname><given-names>A</given-names></name><name><surname>Roychoudhury</surname><given-names>S</given-names></name><name><surname>Panda</surname><given-names>CK</given-names></name></person-group><article-title>Differential association of BRCA1 and BRCA2 genes with some breast cancer-associated genes in early and late onset breast tumors</article-title><source>Ann Surg Oncol</source><year>2004</year><volume>11</volume><fpage>1045</fpage><lpage>1055</lpage><pub-id pub-id-type="pmid">15576832</pub-id><pub-id pub-id-type="doi">10.1245/ASO.2004.02.022</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mizuno</surname><given-names>T</given-names></name><name><surname>Tokuoka</surname><given-names>S</given-names></name><name><surname>Kishikawa</surname><given-names>M</given-names></name><name><surname>Nakashima</surname><given-names>E</given-names></name><name><surname>Mabuchi</surname><given-names>K</given-names></name><name><surname>Iwamoto</surname><given-names>KS</given-names></name></person-group><article-title>Molecular basis of basal cell carcinogenesis in the atomic-bomb survivor population: p53 and PTCH gene alterations</article-title><source>Carcinogenesis</source><year>2006</year><volume>27</volume><fpage>2286</fpage><lpage>2294</lpage><pub-id pub-id-type="pmid">16777989</pub-id><pub-id pub-id-type="doi">10.1093/carcin/bgl107</pub-id></citation></ref></ref-list></back></article> 